Dermatology spot diagnosis

Postgraduate Medical Journal

Volumn 81, Issue 958, 2005, Pages 497-

  Maheux, P ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ESTROGEN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ANAMNESIS; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; HAND INJURY; HUMAN; HYPOTHYROIDISM; LABORATORY TEST; LOW FAT DIET; MALE; RISK FACTOR; XANTHOMA;

ADULT; APOLIPOPROTEINS E; ELBOW; HAND DERMATOSES; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; MALE; MUTATION; XANTHOMATOSIS;

EID: 23844434659     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.035469     Document Type: Article

References (4)

1. Mahley R, Rail S. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Valle D, et al, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001:2753.
2. Mahley RW, Huang Y, Rail SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933-49.
3. Cruz PD Jr, East C, Bergstresser PR. Dermal, subcutaneous, and tendon xanthomas: diagnostic markers for specific lipoprotein disorders. J Am Acad Dermatol 1988;19:95-111.
4. Civeira F, Cenarro A, Ferrando J, et al. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J 1999;138:156-62.